Table 1.
Baseline characteristics of 559 patients with a history of decompensated cirrhosis
| Received DAA after study inclusion (n = 483) | Did not receive DAA after study inclusion (n = 76) | P-value | |
|---|---|---|---|
| Follow-up time in months | |||
| Median (Q1–Q3) | 43.5 [26.6–52.4] | 15.2 [6.2–39.2] | < 0.0001 |
| Age in years | |||
| Median (Q1–Q3) | 56.6 [51.2–63.8] | 56.0 [51.2–63.1] | 0.73 |
| Male gender | 336 (70%) | 47 (62%) | 0.18 |
| BMI (kg/m2) | 0.10 | ||
| < 18.5 | 12 (2%) | 6 (8%) | |
| [18.5, 25] | 229 (48%) | 36 (47%) | |
| [> 25, 30] | 164 (34%) | 23 (30%) | |
| > 30 | 77 (16%) | 11 (14%) | |
| Missing | 1 | 0 | |
| Geographic origin | 0.95 | ||
| Asia | 7 (1%) | 1 (1%) | |
| Eastern Europe | 22 (5%) | 3 (4%) | |
| France | 296 (61%) | 46 (61%) | |
| North Africa | 81 (17%) | 15 (20%) | |
| Other | 60 (12%) | 10 (13%) | |
| Sub-Saharan Africa | 17 (4%) | 1 (1%) | |
| Infection route | |||
| Injecting drug use | 145 (30%) | 32 (43%) | |
| Transfusion | 136 (28%) | 19 (26%) | |
| Other or unknown | 202 (42%) | 23 (31%) | |
| Missing | 0 | 2 | 0.06 |
| Time since HCV diagnosis in years | 0.22 | ||
| Median (Q1–Q3) | 14.2 [7.8–19.9] | 15.1 [5.3–18.5] | |
| Missing | 9 | 5 | |
| HCV treatment history | 0.07 | ||
| Treatment-experienced | 330 (68%) | 44 (58%) | |
| Treatment-naive | 153 (32%) | 32 (42%) | |
| HCV genotype | 0.19 | ||
| 1 | 283 (59%) | 44 (62%) | |
| 2 | 23 (5%) | 5 (7%) | |
| 3 | 102 (21%) | 11 (15%) | |
| 4 | 65 (14%) | 8 (11%) | |
| 5/6/7 | 5 (1%) | 3 (4%) | |
| Missing | 5 | 5 | |
| Child–Pugh score | 0.003 | ||
| A | 233 (57%) | 20 (37%) | |
| B | 150 (37%) | 25 (46%) | |
| C | 26 (6%) | 9 (17%) | |
| Missing | 74 | 22 | |
| MELD score | 0.003 | ||
| < 13 | 335 (70%) | 37 (51%) | |
| [13; 20] | 117 (25%) | 31 (42%) | |
| > 20 | 25 (5%) | 5 (7%) | |
| Missing | 6 | 4 | |
| Diabetes | 0.53 | ||
| No | 372 (77%) | 61 (80%) | |
| Yes | 111 (23%) | 15 (20%) | |
| Arterial hypertension | 0.55 | ||
| No | 328 (68%) | 49 (64%) | |
| Yes | 155 (32%) | 27 (36%) | |
| Anaemia | 0.11 | ||
| No | 338 (70%) | 45 (61%) | |
| Yes | 144 (30%) | 29 (39%) | |
| Missing | 1 | 2 | |
| Albumin (g/L) | 0.20 | ||
| Median (Q1–Q3) | 35.4 (30.8–39.8) | 34 (29–38.6) | |
| Missing | 10 | ||
| Prothrombin time (%) | 0.06 | ||
| Median (Q1–Q3) | 74.5 (62–87) | 70 (56–81) | |
| Missing | 11 | 5 | |
| Platelet count (/µL) | 0.58 | ||
| Median (Q1–Q3) | 93,000 (64,000–136,000) | 91,000 (61,000–148,000) | |
| Missing | 10 | 1 | |
| Alanine aminotransferase (UI/L) | < 0.0001 | ||
| Median (Q1–Q3) | 60 (41–95) | 43 (28–61) | |
| Missing | 4 | 3 | |
| Aspartate aminotransferase (UI/L) | 0.09 | ||
| Median (Q1–Q3) | 78 (53–111) | 63.5 (39–108) | |
| Missing | 4 | 2 | |
| Alpha-fetoprotein (ng/mL) | 0.40 | ||
| Median (Q1–Q3) | 7 (3.9–13.3) | 6 (3.8–11.1) | |
| Missing | 49 | 9 | |
| Bilirubin (mg/L) | 0.08 | ||
| Median (Q1–Q3) | 21 (13.6–32) | 25.5 (14–44) | |
| Missing | 8 | 1 | |
| Past excessive alcohol use | 0.23 | ||
| No | 252 (52%) | 34 (45%) | |
| Yes | 231 (48%) | 42 (55%) | |
| Excessive alcohol use at study inclusion | 0.001 | ||
| No | 383 (98%) | 52 (91%) | |
| Yes | 6 (2%) | 5 (9%) | |
| Missing | 94 | 19 | |
| Smoking | 0.01 | ||
| No | 278 (58%) | 32 (42%) | |
| Yes | 205 (42%) | 44 (58%) | |
| Time since decompensation of cirrhosis in months | 0.67 | ||
| Med [IQR] | 27.1 [7.4–95.7] | 21 [4.8–84.0] | |
| Missing | 10 | 4 | |
| Type of decompensated cirrhosis | |||
| Ascites | 159 (36%) | 24 (36%) | |
| Icterus | 113 (25%) | 20 (30%) | |
| Encephalopathy | 36 (8%) | 5 (8%) | |
| Haemorrhage | 136 (31%) | 17 (26%) |
Values in bold correspond to significant differences between the 2 groups (p < 0.05)
The median follow-up time was 39.7 [IQR 22.7–51.0] months. DAA treatment began for 483 patients after a median time from study inclusion of 0.9 [0–6.2] months